United Therapeutics (UTHR) Misses Q2 EPS, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
Tweet
Share
E-mail
Get Alerts UTHR Hot Sheet
Price: $592.84 --0%
EPS Growth %: -13.3%
Financial Fact:
Cost of product sales: 23.6M
Today's EPS Names:
PHAR, EEFT, INIO, More
EPS Growth %: -13.3%
Financial Fact:
Cost of product sales: 23.6M
Today's EPS Names:
PHAR, EEFT, INIO, More
Join SI Premium – FREE
United Therapeutics (NASDAQ: UTHR) reported Q2 EPS of $2.41, $1.97 worse than the analyst estimate of $4.38. Revenue for the quarter came in at $466.9 million versus the consensus estimate of $460.67 million.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JetBlue Airways (JBLU) Misses Q3 EPS by 6c, Misses on Revenue
- Independent Bank (IBCP) Misses Q3 EPS by 11c
- H2O America (HTO) Misses Q3 EPS by 16c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
